Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors : results from the Pediatric HIV/AIDS Cohort Study
© 2017 British HIV Association..
OBJECTIVES: Dyslipidaemia is common in perinatally HIV-infected (PHIV) youth receiving protease inhibitors (PIs). Few studies have evaluated longitudinal lipid changes in PHIV youth after switch to newer PIs.
METHODS: We compared longitudinal changes in fasting lipids [total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and TC:HDL-C ratio] in PHIV youth enrolled in the Pediatric HIV/AIDS Cohort Study (PHACS) Adolescent Master Protocol (AMP) study who switched to atazanavir/ritonavir (ATV/r)- or darunavir/ritonavir (DRV/r)-based antiretroviral therapy (ART) from an older PI-based ART and those remaining on an older PI. Generalized estimating equation models were fitted to assess the association of a switch to ATV/r- or DRV/r-based ART with the rate of change in lipids, adjusted for potential confounders.
RESULTS: From 2007 to 2014, 47 PHIV children/adolescents switched to ATV/r or DRV/r, while 120 remained on an older PI [primarily lopinavir/r (72%) and nelfinavir (24%)]. Baseline age ranged from 7 to 21 years. After adjustment for age, Tanner stage, race/ethnicity, and HIV RNA level, a switch to ATV/r or DRV/r was associated with a more rapid annual rate of decline in the ratio of TC:HDL-C. (β = -0.12; P = 0.039) than remaining on an older PI. On average, TC declined by 4.57 mg/dL/year (P = 0.057) more in the switch group. A switch to ATV/r or DRV/r was not associated with the rate of HDL-C, LDL-C, or TG change.
CONCLUSIONS: A switch to ATV/r or DRV/r may result in more rapid reduction in TC and the TC:HDL-C ratio in PHIV youth, potentially impacting long-term cardiovascular disease risk.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
HIV medicine - 19(2018), 3 vom: 12. März, Seite 175-183 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jao, J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.03.2019 Date Revised 09.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/hiv.12566 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM278261337 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM278261337 | ||
| 003 | DE-627 | ||
| 005 | 20231225020140.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/hiv.12566 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0927.xml |
| 035 | |a (DE-627)NLM278261337 | ||
| 035 | |a (NLM)29159965 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jao, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors |b results from the Pediatric HIV/AIDS Cohort Study |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2019 | ||
| 500 | |a Date Revised 09.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2017 British HIV Association. | ||
| 520 | |a OBJECTIVES: Dyslipidaemia is common in perinatally HIV-infected (PHIV) youth receiving protease inhibitors (PIs). Few studies have evaluated longitudinal lipid changes in PHIV youth after switch to newer PIs | ||
| 520 | |a METHODS: We compared longitudinal changes in fasting lipids [total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and TC:HDL-C ratio] in PHIV youth enrolled in the Pediatric HIV/AIDS Cohort Study (PHACS) Adolescent Master Protocol (AMP) study who switched to atazanavir/ritonavir (ATV/r)- or darunavir/ritonavir (DRV/r)-based antiretroviral therapy (ART) from an older PI-based ART and those remaining on an older PI. Generalized estimating equation models were fitted to assess the association of a switch to ATV/r- or DRV/r-based ART with the rate of change in lipids, adjusted for potential confounders | ||
| 520 | |a RESULTS: From 2007 to 2014, 47 PHIV children/adolescents switched to ATV/r or DRV/r, while 120 remained on an older PI [primarily lopinavir/r (72%) and nelfinavir (24%)]. Baseline age ranged from 7 to 21 years. After adjustment for age, Tanner stage, race/ethnicity, and HIV RNA level, a switch to ATV/r or DRV/r was associated with a more rapid annual rate of decline in the ratio of TC:HDL-C. (β = -0.12; P = 0.039) than remaining on an older PI. On average, TC declined by 4.57 mg/dL/year (P = 0.057) more in the switch group. A switch to ATV/r or DRV/r was not associated with the rate of HDL-C, LDL-C, or TG change | ||
| 520 | |a CONCLUSIONS: A switch to ATV/r or DRV/r may result in more rapid reduction in TC and the TC:HDL-C ratio in PHIV youth, potentially impacting long-term cardiovascular disease risk | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a atazanavir | |
| 650 | 4 | |a children | |
| 650 | 4 | |a darunavir | |
| 650 | 4 | |a lipids | |
| 650 | 4 | |a longitudinal | |
| 650 | 4 | |a perinatally HIV-infected | |
| 650 | 7 | |a HIV Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 650 | 7 | |a Atazanavir Sulfate |2 NLM | |
| 650 | 7 | |a 4MT4VIE29P |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Darunavir |2 NLM | |
| 650 | 7 | |a YO603Y8113 |2 NLM | |
| 700 | 1 | |a Yu, W |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, K |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, T L |e verfasserin |4 aut | |
| 700 | 1 | |a Karalius, B |e verfasserin |4 aut | |
| 700 | 1 | |a Geffner, M E |e verfasserin |4 aut | |
| 700 | 1 | |a DiMeglio, L A |e verfasserin |4 aut | |
| 700 | 1 | |a Mirza, A |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, J S |e verfasserin |4 aut | |
| 700 | 1 | |a Silio, M |e verfasserin |4 aut | |
| 700 | 1 | |a McFarland, E J |e verfasserin |4 aut | |
| 700 | 1 | |a Van Dyke, R B |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobson, D |e verfasserin |4 aut | |
| 700 | 0 | |a Pediatric HIV/AIDS Cohort Study (PHACS) Adolescent Master Protocol (AMP) study |e verfasserin |4 aut | |
| 700 | 1 | |a Yogev, Ram |e investigator |4 oth | |
| 700 | 1 | |a Sanders, Ann |e investigator |4 oth | |
| 700 | 1 | |a Malee, Kathleen |e investigator |4 oth | |
| 700 | 1 | |a Hunter, Scott |e investigator |4 oth | |
| 700 | 1 | |a Shearer, William |e investigator |4 oth | |
| 700 | 1 | |a Paul, Mary |e investigator |4 oth | |
| 700 | 1 | |a Cooper, Norma |e investigator |4 oth | |
| 700 | 1 | |a Harris, Lynnette |e investigator |4 oth | |
| 700 | 1 | |a Purswani, Murli |e investigator |4 oth | |
| 700 | 1 | |a Baig, Mahboobullah |e investigator |4 oth | |
| 700 | 1 | |a Cintron, Anna |e investigator |4 oth | |
| 700 | 1 | |a Puga, Ana |e investigator |4 oth | |
| 700 | 1 | |a Navarro, Sandra |e investigator |4 oth | |
| 700 | 1 | |a Garvie, Patricia A |e investigator |4 oth | |
| 700 | 1 | |a Blood, James |e investigator |4 oth | |
| 700 | 1 | |a Burchett, Sandra K |e investigator |4 oth | |
| 700 | 1 | |a Karthas, Nancy |e investigator |4 oth | |
| 700 | 1 | |a Kammerer, Betsy |e investigator |4 oth | |
| 700 | 1 | |a Wiznia, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Burey, Marlene |e investigator |4 oth | |
| 700 | 1 | |a Nozyce, Molly |e investigator |4 oth | |
| 700 | 1 | |a Dieudonne, Arry |e investigator |4 oth | |
| 700 | 1 | |a Bettica, Linda |e investigator |4 oth | |
| 700 | 1 | |a Bulkley, Garcia |e investigator |4 oth | |
| 700 | 1 | |a Ivey, Latreaca |e investigator |4 oth | |
| 700 | 1 | |a Grant, Mitzie |e investigator |4 oth | |
| 700 | 1 | |a Knapp, Katherine |e investigator |4 oth | |
| 700 | 1 | |a Allison, Kim |e investigator |4 oth | |
| 700 | 1 | |a Wilkins, Megan |e investigator |4 oth | |
| 700 | 1 | |a Acevedo-Flores, Midnela |e investigator |4 oth | |
| 700 | 1 | |a Rios, Heida |e investigator |4 oth | |
| 700 | 1 | |a Olivera, Vivian |e investigator |4 oth | |
| 700 | 1 | |a Gabriel, Medea |e investigator |4 oth | |
| 700 | 1 | |a Sirois, Patricia |e investigator |4 oth | |
| 700 | 1 | |a Spector, Stephen A |e investigator |4 oth | |
| 700 | 1 | |a Norris, Kim |e investigator |4 oth | |
| 700 | 1 | |a Nichols, Sharon |e investigator |4 oth | |
| 700 | 1 | |a McFarland, Elizabeth |e investigator |4 oth | |
| 700 | 1 | |a Darrow, Juliana |e investigator |4 oth | |
| 700 | 1 | |a Barr, Emily |e investigator |4 oth | |
| 700 | 1 | |a Harding, Paul |e investigator |4 oth | |
| 700 | 1 | |a Scott, Gwendolyn |e investigator |4 oth | |
| 700 | 1 | |a Alvarez, Grace |e investigator |4 oth | |
| 700 | 1 | |a Cuadra, Anai |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t HIV medicine |d 1999 |g 19(2018), 3 vom: 12. März, Seite 175-183 |w (DE-627)NLM116282541 |x 1468-1293 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2018 |g number:3 |g day:12 |g month:03 |g pages:175-183 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/hiv.12566 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2018 |e 3 |b 12 |c 03 |h 175-183 | ||